Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of allogeneic iPS cell-derived cardiomyocyte sheet transplantation
jRCT1050260111Recruiting
- Start
- Jul 2026
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of Human (allogeneic) iPS cell derived-cardiomyocyte sheet in dilated cardiomyopathy (DCM) and ischaemic cardiomyopathy (ICM), sponsored by None. Primary endpoint: Overall survival time. Started Jul 2026; status: recruiting.
02
Drugs
Human (allogeneic) iPS cell derived-cardiomyocyte sheet
03
Conditions
dilated cardiomyopathy (DCM)ischaemic cardiomyopathy (ICM)
Beyond the preview
Go deeper on jRCT1050260111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1050260111.